Diabetic nephropathy
Conditions
Interventions
Placebo group:placebo
Sponsors
Tianjin Medical University Metabolic Diseases Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Aged 40 to 70 years old male or female; (2) Voluntarily participate in this clinical study, the patients signed a written informed consent before the start of the study; (3) In accordance with the diagnostic criteria for diabetic nephropathy[37]; Consistent with the Mogensen phase IV, that is, persistent large amounts of albumin urine (urinary albumin excretion rate > 200 mu g/min or proteinuria greater than 500mg/d); (4) 24 hours urinary protein greater than or equal to 1g; (5) Estimated glomerular filtration rate (eGFR, calculated according to CKD-EPI formula) greater than or equal to 30mL/min/1.73m2 (equivalent to chronic kidney disease stage 1-3); (6) ARB drug therapy has been accepted and the patient's condition is stable. Selected patients shoud meet all of the above requirements.
Exclusion criteria
Exclusion criteria: (1) Patients with type 1 diabetes mellitus or secondary diabetes mellitus; (2) Allergy to Tripterygium wilfordii Hook F; (3) The use of immunosuppressive agents other than Tripterygium wilfordii Hook F; (4) Pregnancy, breast-feeding or pregnancy, lactation in the course of the study; (5) Impaired liver function: Two times of ALT or AST levels exceed the upper limit of the normal value; (6) Blood white blood cell 180/100mmHg, and difficult to control; (8) Acute infection: happen within 1 month before the study; (9) Serum creatinine levels increased by more than 50%, or the inability to control the severe hyper potassium (serum potassium >6.0mmol/L), or unavailable use of such drugs,for example double renal artery stenosis; (10) Occurrence of serious cardiac and cerebral vascular events: heart failure, angina, myocardial infarction, cerebral infarction, cerebral hemorrhage, etc within 6 months before the study; (11) Poor compliance (as judged by the investigator); (12) Participat in other drug clinical trials within 6 months before into the group; (13) Other researchers think that the situation is not suitable for the selected.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary albumin creatinine ratio;Changes in miRNA expres; | — |
Secondary
| Measure | Time frame |
|---|---|
| 8-OHdG;mindin;N- acetyl-Beta-D- glucosidase;Beta 2-microglobulin;a-Galactosidase; | — |
Countries
China
Contacts
Public ContactChunjun Li
Tianjin Medical University Metabolic Diseases Hospital
Outcome results
None listed